Seelos Therapeutics, Inc. · OTC:SEELQ
Seelos Therapeutics — Technical Presentation (May 2021)
11 slides from Seelos Therapeutics's technical presentation, May 17, 2021
Slide 1: Conference Call to Discuss Open-Label Top Line Data for SLS-002
Exhibit 99.2 Conference Call to Discuss Open-Label ——— Top Line Data for SLS-002 May 17, 2021
Slide 2: Forward-Looking Statements
FORWARD-LOOKING STATEMENTS This comorate presentation includes certain forward-looking statements within the meaning of Section 21E ofthe Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Refom Act of 1995, These forward-looking statements include, but are not limite
Slide 3: Conference Call Speakers
CONFERENCE CALL SPEAKERS « Raj Mehra, Ph.D. + Chairman and CEO of Seelos Therapeutics ¢ Tim Whitaker, M.D. * Chief Medical Officer of Seelos Therapeutics * David V. Sheehan M.D. + Distinguished University Health Professor Emeritus, University of South Florida College of Medicine
Slide 4: Suicide Is a Global Epidemic
SUICIDE IS A GLOBAL EPIDEMIC + According to WHO, ~800,000 people globally die yearly by suicide — one person every 40 seconds + Inthe US, suicide is the 2™ leading cause of death in individuals between the ages of 10-34 and the 4" leading cause of death in ages 35-54 + In 2019, ~48,000 suicides occu
Slide 5: Proof-of-Concept Trial Design for SLS-002
PROOF-OF-CONCEPT TRIAL DESIGN FOR SLS-002 Design (PoC Study) “Two-part — Open label (n=17) followed by double blind (n~120) +Initiated in hospital, followed by outpatient phase once stabilized + Two-week (16 days) treatment period (~7 days inpatient / 9 days outpatient) + Dosing 2xweek for total of
Slide 6: Study Enrollment Criteria
UDY ENROLLMENT CRITERIA This study enrolled 17 patients diagnosed with MDD requiring psychiatric hospitalization due to significant risk of suicide and: * Baseline total score of 2 28 points on the Montgomery-Asberg Depression Rating Scale (MADRS) * Score of 5 or 6 on MADRS lItem-10 * Total score of
Slide 7: Detailed Summary of MADRS and MADRS Item-10
DETAILED SUMMARY OF MADRS AND MADRS ITEM-10 MADRS +76.5% response rate on Day 1; 92.9% response rate on Day 16; and 100% response rate on Day 29 (14 days after the last dose on Day 15) +Remission rate on Day 1 = 35.3%; Day 16 = 78.6%; and Day 29 = 76.9% «Total Score (baseline) = 39.4; Day 1, mean =
Slide 8: Detailed Summary of Suicide Scales Data
DETAILED SUMMARY OF SUICIDE SCALES DATA CGIS-SI/B *94% patients had 2 1 point within-patient change from their baseline on Day 1 and 100% of patients on Day 16 had = 1 point change and 86% had 2 or 3 point within-patient change from their baseline +Baseline = 3.8; Day 1, mean = 1.6; and Day 16, mean
Slide 9: Detailed Summary of Safety Results
DETAILED SUMMARY OF SAFETY RESULTS Clinician Administered Dissociative States Scale (CADSS) *Change from baseline (at 40 minutes) = 3.8 after first dose and 1.0 at 1 hour post first dose, 2.6 on Day 4 (after second dose) and 0.3 on Day 8 (after third dose) Hemodynamic Effects «Systolic BP: Baseline
Slide 10: SLS-002 Showed Clinical Improvements Across All Four Scales
SLS-002 SHOWED CLINICAL IMPROVEMENTS ACROSS ALL FOUR SCALES BAS EINE, DAYa DAY; 0) 7) i) MADRS 39.4 14.5 7.4 (0-60 scale, $12 is remission) CGIS-SIB 3.8 1.6 aa (1-5 scale, 1=not at all, 5=extremely suicidal) $-STS 22.4 dee 0.0 (0-52 scale, higher score equated to higher suicidality) PGIS-SI/B 3.5 1.
Slide 11: [email protected]
Seelos Therapeutics — Technical Presentation (May 2021) on 6ix